A Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03939871 |
Recruitment Status : Unknown
Verified June 2020 by Peng Yuan, Chinese Academy of Medical Sciences.
Recruitment status was: Recruiting
First Posted : May 7, 2019
Last Update Posted : June 23, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Hormone Receptor Positive Advanced Breast Cancer | Drug: fluvestrant + oral vinorelbine | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 30 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Phase II Study of Fluvestrant Combined With Oral Vinorelbine in Hormone Receptor-positive Advanced Breast Cancer |
Actual Study Start Date : | December 12, 2017 |
Estimated Primary Completion Date : | December 12, 2020 |
Estimated Study Completion Date : | December 12, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Single arm
Fluvestrant in combination with oral Vinorelbine Fluvestrant: administered at a dose of 0.5g once im every 28 days. Vinorelbine: administered at a dose of 60mg/kg once a week for 3 weeks p.o. every 28 days.
|
Drug: fluvestrant + oral vinorelbine
Eligible patients will be treated with the fluvestrant + oral vinorelbine regimen until the disease progresses or intolerable toxicity
Other Name: there is no other intervention name |
- Progression-free survival (PFS) [ Time Frame: approximately 1.5 years ]PFS will be defined as the time from first dose of study drug until documentation of disease progression or death from any cause
- Objective response rate (ORR) [ Time Frame: approximately 6 months ]The ORR will be calculated as the proportion of patients in the Efficacy Evaluable patient Set who achieve complete response (CR) and partial response (PR)
- Incidence and Severity of adverse events [ Time Frame: approximately 1.5 years ]hematologic toxicity,hepatotoxicity and so on

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 70 Years (Adult, Older Adult) |
Sexes Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age between 18 and 75 year-old women; Pathologically or cytologically confirmed breast cancer; Hormone receptor-positive
- ECOG score: 0-1, expected survival time ≥ 3months;
- Recurrence after adjuvant therapy or metastatic breast cancer and chemotherapy naïve in the metastatic setting or had one prior regimen for metastatic breast cancer.
- Patients must have measurable disease according to RECIST criteria Version 1.1. Bone metastases lesions were excluded.
- The patients have adequate hematologic and organ function.
Exclusion Criteria:
- Patients with symptomatic brain metastases.
- Patients who are known or suspected to be allergic to the active ingredient or excipients of the investigational drug.
- Received ≥1 standard chemotherapy regimen (excluding endocrine therapy) for advanced breast cancer.
- Participation in other clinical trials within 4 weeks before enrollment.
- Severe cardiovascular disease, including history of congestive heart failure, acute myocardial infarction within 6 months before enrollment, transmural myocardial infarction measured by ECG, uncontrolled arrhythmia, angina requiring therapy, clinically significant valvular heart disease, uncontrolled hypertension.
- Severe or uncontrolled infection.
- Any factors that affect the oral administration and absorption of drugs (such as inability to swallow, gastrointestinal resection, chronic diarrhea and intestinal obstruction, etc.);
- Active malignancy in the past 5 years (other than carcinoma in situ of the cervix or basal cell carcinoma of the skin).
- Patients who are pregnant , breastfeeding ,or refuse to use adequate contraception during the course of participation.
- Need to concurrent other cancer therapy(other than palliative care for non-target lesions).
- Other ineligible conditions according to the researcher's judgment.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03939871
Contact: Peng Yuan, M.D. | 13501270834 | yuanpeng01@hotmail.com | |
Contact: Xue Wang, M.D. | 13811967690 | wxyxyuki@163.com |
China, Beijing | |
National Cacner Center/ Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College | Recruiting |
Beijing, Beijing, China, 100021 | |
Contact: Peng Yuan 010-87787240 yuanpeng01@hotmail.com |
Principal Investigator: | Peng Yuan | Cancer Institute and Hospital, Chinese Academy of Medical Sciences |
Responsible Party: | Peng Yuan, Principal Investigator, Chinese Academy of Medical Sciences |
ClinicalTrials.gov Identifier: | NCT03939871 |
Other Study ID Numbers: |
NCC1564 |
First Posted: | May 7, 2019 Key Record Dates |
Last Update Posted: | June 23, 2020 |
Last Verified: | June 2020 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Breast Neoplasms Neoplasms by Site Neoplasms Breast Diseases Skin Diseases Vinorelbine |
Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action |